Last $0.71 USD
Change Today -0.005 / -0.70%
Volume 650.6K
RNN On Other Exchanges
As of 6:40 PM 11/20/14 All times are local (Market data is delayed by at least 15 minutes).

rexahn pharmaceuticals inc (RNN) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/14 - $1.85
52 Week Low
11/25/13 - $0.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

rexahn pharmaceuticals inc (RNN) Related Businessweek News

No Related Businessweek News Found

rexahn pharmaceuticals inc (RNN) Details

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer. The company has three clinical stage oncology candidates: Archexin, RX-3117, and SupinoxinTM (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. The company is based in Rockville, Maryland.

16 Employees
Last Reported Date: 03/21/14

rexahn pharmaceuticals inc (RNN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $380.8K
President and Chief Operating Officer
Total Annual Compensation: $268.8K
Founder, Chairman of the Board and Chief Scie...
Total Annual Compensation: $319.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $270.1K
Compensation as of Fiscal Year 2013.

rexahn pharmaceuticals inc (RNN) Key Developments

Rexahn Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2014

Rexahn Pharmaceuticals, Inc. reported earnings results for the third quarter ended September 30, 2014. For the quarter, the company reported net loss of $1.9 million, or $0.01 per share, for the three months ended September 30, 2014, compared to a net loss of $2.1 million, or $0.02 per share, for the three months ended September 30, 2013. Included in net loss for the three months ended September 30, 2014 and 2013 is an unrealized gain (loss) on the fair value of warrants of $1.2 million and ($0.2 million), respectively. Loss from operations was $3.1 million and $1.8 million for the three months ended September 30, 2014 and 2013, respectively.

Rexahn Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 10:20 AM

Rexahn Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 10:20 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Peter D. Suzdak, Chief Executive Officer and Director, Tae Heum Jeong, Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Secretary.

Rexahn Pharmaceuticals, Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for Rx-3117 in Treatment of Pancreatic Cancer

Rexahn Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its drug RX-3117 for the treatment of patients with pancreatic cancer. RX-3117 is a next generation, cancer-specific nucleoside analog. Rexahn is currently enrolling patients in a Phase Ib clinical trial in cancer patients and expects to complete this trial in the first quarter of 2015. The FDA's office of Orphan Drug Products grants orphan status to support development of medicines for rare disorders, defined as diseases that affect fewer than 200,000 people in the United States. Orphan drug designation provides Rexahn with certain benefits, including limited market exclusivity upon regulatory approval if received, exemption of FDA application fees and tax credits for qualified clinical trials. Preclinical studies have shown that RX-3117 maintains its anti-tumor activity in human cancer cell lines that are resistant to gemcitabine, a chemotherapy drug used to treat pancreatic cancer. Gemcitabine resistance represents a major problem in the treatment of cancer patients. In pancreatic cancer patients who have been treated with gemcitabine, up to 40% of patients became resistant to gemcitabine after 30 days. RX-3117 has shown to be effective in treating cancer cells that have become gemcitabine resistant. If the results of Phase Ib trial and future trials show similar results in gemcitabine resistant patients, this would represent a major breakthrough in the treatment of pancreatic cancer patients.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RNN:US $0.71 USD -0.005

RNN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RNN.
View Industry Companies

Industry Analysis


Industry Average

Valuation RNN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REXAHN PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at